<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 57 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page56.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=57">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 57 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 57</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=57"><img src="../thumb/57.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>26 / 2020-04                                                        Central Nervous System - 1.5.3
   elevat., pts.at risk of aspirat.pneum., monit. high risk suic.pts., leu-  Dosage: Psychot.disords: Init.5-10 mg/day with target dos.of   range of 300-450 mg/day. Adjust.dos.within 150-750 mg / day range
   copen./neutropen., meds. induc.bone marrow depress./toxic., bone   10 mg/day within sever.days. If indic.dos.adjustm.should occur pro-  depend.on clinic.response & tolerab.
                                                                                     st
   marrow depress., hypereosnophil.condits., myeloproliferat. dis., reg.  ceed.at interv. of not less than 1 wk.  Bipol.disord.assoc.manic episod: Tot.dly.dos. for 1  4 days: Day
   BP monit.of pts.&gt;65 yrs.     Ac.man.in bipol.disord: Init.dos:10 mg once dly. Dos.adjustm.  1: 100 mg, day 2: 200 mg, day 3: 300 mg & day 4: 400 mg. Furth.dos.
   Drug interactions: May antagon.effs.of levodopa & dopamine   within range of 5-20 mg/day to occur at interv.of not less than 24   adjustm.up to 800 mg/day by day 6 in increm.of no great.than 200
   agonists, may enhanc.effs.of cert. antihypertens., CYP1A2 induc.  hrs.if indicat.  mg/day. Adjust dos.accord.to clinic.respon. & tolerabil. with range of
   incr.clear.& CYP1A2 inhibit.reduc.clear., reduc.bioavail.with acti-  Prev.recurr.in bipol.disord: Recomm.start.dos: 10 mg/ day. For   200-800 mg/day. Usual effect.dos.: 400-800 mg/day.
   vat. charc., fluoxetine incr.conc.& decr.clear., metabol.poss.induc.by   those receiv. Prexolan treatm. for manic episod.cont.ther.at same   Elderly: Init.25 mg/day, theraft.incr.dly.dos.in increm. of 25-50 mg.to
   smok.& carbamazepine.        dos. Incr.dos.to great.than recomm.start.dos.within range of 5-20 mg/  an effect.dos.poss.low. than young.pts.
   PERIZAL, Specpharm [P/S]     day only aft. clinic.assessm.at interv.of not less than 24 hrs. Safety   Contraindications: Safety in pregn.& lactat. not est., safety & effic.
                                                              in childr.& adolesc.und.18 yrs. not est., safety in sev.liv.& ren.funct.
                                of dos.above 20 mg/day not eval. Improvem.in pt.condit.may take
   Risperidone                  sev.days to wks.              impairm.not est., not indic.for elderly pts.with dement.exhibit. behav.
   Indications: Ac.& chron.schizophren.psychos.& relat. psychos.  (S5) POWD.FOR SOL.FOR INJ. 43/2.6.5/0911  disturbs., co-admin.with cytochrome P450 inhibits., Lapp-Lact.defic.,
   where posit.&/or negat.sympts.are promin., behav.disturbs.in pts.  Indications: Control of agitat./disturb.behav.in schizophren. &   gluc-galact.malabsorpt.
   with dement.when aggressiven./activ.disturbs./psychot.sympts.are   relat.psychos.and ac.man.assoc. with bipol.I disord.when oral ther.  Side effects: Hyperglycaem.sometim. extreme assoc. with ketoaci-
   promin., conduct & disrupt.behav.disords.in childr. 5-12 yrs.with sub-  not appropr.  dos./hyperosmol.coma/death, bld. disords., hypersens.reacts.incl.an-
   aveg.intellect.funct./ ment. retard.where destruct.behav.is promin.  720715-001: 10 mg, 1 vial, R142,55  aphylax., Stev. John.syndr., diab.mellit./exacerbat.of pre-exist. diab.,
   (S5) TABS, A40/2.6.5/0706, 0707, 0708, 0709  Dosage: Reconstit.with ster.water for inj.only. IM use only. Discont.  psych.disords., somnol., dizzin., headache, anx., syncope, extrapyra-
   712617-001: 0,5 mg, 30, R152,61  IM treatm.and init. oral treatm.as soon as clinic.appropr. Admin.in   mid.sympt./ syndr., seiz., dry eyes, blurr.vis., eye lens chang. with longt.
   712618-001: 1 mg, 30, R233,10  healthcare facility. First est.respons.& tolerab.with oral olanzapine
   712619-001: 2 mg, 30, R498,61  in pts.never admin.olanzapine bef.   use, ear/back/chest pain, tachycard., QTc prolongat., postur.hypotens.,
                                                              hypertens., ven. thromboembol., rhinit., GI disturbs., weight gain.,
   712621-001: 3 mg, 30, R747,39  Recomm.dos:10 mg as sngl.IMI. Bas.on indiv clinic. status a 2   nd
   Dosage: Schizophren: When switch.from other antipsychot. & if   10 mg dos.2 hrs.aft.1  inj.and 3  inj.of up to 10 mg 4 hrs.aft.2  inj.  jaund., hepatit., rash, myalg., UTI, priapism, galactorrh., dysarthr.,
                                         st
                                             rd
                                                          nd
                                                              asthen., fev., periph.oed., elev. ser.transamin./cholesterol & triglyc-
   medic.appropriate discont.prev. treatm.grad.& if switch.from depot   If oral supplementat.reqd.combin.tot.dos.of both formulat.not to
   antipsychot. init. Perizal in place of next sched.inj. Re-eval. need for   exceed.max.oral dos.of 20 mg dly. Safety of tot.dly dos.great.than   eride, decr. thyroid horm.lev., orthostat.hypotens.esp. elderly dur.init.
                                                              dos.titrat., tard.dyskines., neurolept. malign.syndr., ac.withdr.sympt.
   cont.exist.anti-Parkinson meds.period.  30 mg not eval.
   Dos. above 10 mg/day have not been shown to be superior in effic.&   Contraindications: Known narrow-angl.glauc. risk, safety & effic.in   Special precautions: Known CV/cerebrovasc. dis./ condits.pre-
   may incr.incid.of S/E & should only be consid.aft.eval.risk vs.benef.   childr.und. 18 yrs.not est., safety in pregn.& lactat.not est., dement.-  dispos.to hypotens.esp.elderly, monit.gluc.contr.of exist.diabet./hy-
   Add benzodiazep. if addit.sedat.reqd.  relat. psychos., effic.for more than 6 wks.not est.in control.trials.  perglycaem. sympt.in those at risk, pts.who devel. hyperglycaem.
   Adults: Indiv. Admin.1-2xdly. Init.2 mg/day.incr. to 4 mg on 2nd   Side effects: Hyperglycaem.somet.extr.& assoc. with diabet.  sympt.dur.ther.should undergo fast. bld. gluc.test,cont.anti-diab.
   day, indiv.furth.if reqd. Usual optim. dos.is 4-8 mg/day. Max.tot.dly.  ketoacidos./coma hyperosmol.& death, bld. dyscras., allerg.reacts.,   meds.poss.necess. despite ther.discont., concom.antihypertens./
   dos: 16 mg/day. Elderly: Init.0,5 mg 2x dly.adjust.in 0,5 mg 2xdly.   GI disords., weight gain, incr.appet., psych.disords., hypertriglyceri-  meds. prolong.QTc interv., concom.alcoh./other central. act.meds.,
   increm.to 1-2 mg 2x dly.     daem., elev.cholest.lev., diab. devel./exacerbat., anx., somnol., diz-  hepat.cytochrome P450 enzym. induc., elderly esp.dur.init.dos.per.,
   Behav.disturbs.in pts.with dement: Init. 0,25 mg 2xdly. Indiv.if   zin., headache, akathis., parkinsonism, dyskines., asthen., CNS effs.,   ren./hepat. impairm., consid.discont.ther.if tard.dyskines.S&S occur,
   necess.in increm.of 0,25 mg 2xdly.not more freq.than every other day.   abnorm.gait, fall., trem., speech/movem. disord., extrapyramid.eff.,   seiz.hist., discont.ther.& admin.appropr. treatm. in case of neurolept.
   Optim.dos: 0,5 mg 2xdly.with some benefit. from dos.of up to 1 mg   seiz., dyston., tard. dyskines., neurolept.malign.syndr., discontinuat.   malign.syndr., withdr. grad., rebound psychos., reduc.dos.with non-
   2xdly. Once target.dos. reach.consid.once dly.dos. Ongoing evaluat.&   sympt., amblyop., chest/abdom. /joint/extremit. pain, bradycard.,   induc. eg. sod.valproate.
   justificat. of cont.treatm.  tachycard., QTc prolongat., ventric. tachycard./fibrillat., sudd.death,   Drug interactions: CNS eff.of CNS depress.& alcoh. potent., anti-
   Conduct & disrupt.behav.disords.in childr.5-12 yrs: &lt;50 kg:   orthostat.hypotens., periph. oed., ven. thromboembol., pulm.embol.,   hypertens.eff.of antihypertens. poss. enhanc.with concom.use, act.
   Init.0,01 mg/kg once dly. Indiv. adjust. in increm.of 0,01 mg/kg once   rhinit., pneum., cough, hypoventilat., pharyngit., pancreatit., ALT/AST   of dopaminerg. antagon., incr.clear.with concom.carbamazepine/
   dly.every other day if reqd. Recom.maint.dos: 0,02-0,04 mg/ kg once   elev., hepatit., skin/photosens.reacts., alopec., rhabdomyolys., urin.  phenytoin/ barbits./rifampicin/thioridazine.
   dly. Mean dos: 0,03 mg/kg once dly. Ongoing evaluat.& justificat.  incont./hesitat., menstr.chang., priapism, fev., fatig., hypotherm., IM   QUETIAPINE BIOTECH, Biotech [P/S]
   of cont.treatm.              use also hypotens.and/or bradycard.  Quetiapine
   Contraindications: Safety & effic.in childr.und. 5 yrs.for conduct &   Special precautions: Per.assessm.advis.for maint.treatm.& cont.  Indications: Schizophren., manic episod.assoc. with bi-polar disord.
   other disrupt.behav.disords. not est., Lewy body dement., safety in   at low.dos.need.to maint. remiss., cholinerg.syndr.poss.on discont.,   for which safety & effic. beyond 12 wks. not demonstrat.
   pregn.& lactat.not est., safety & effic.in childr.und.15 yrs. for schizo-  discont. grad., elev.prolact. lev.persist.modest.dur.chron. admin., incr.  (S5) TABS. 45/2.6.5/0212, 0213, 0214, 0215
   phren. not est., galact.lintol., Lapp defic., gluc.-galact.malabsorpt.  mammary gland neoplasms consid. prolact. mediat.report.in rodents   721744-001: 25 mg, 100, R277,92
   Side effects: Tard.dyskines.most.in elderly & esp. elderly fem., neu-  on chron. antipsychot. medicat., discont.ther.if S&S of neurolept. ma-  721745-001: 100 mg, 100, R518,02
   rolept.malign.syndr., hyperglycaem. assoc.with ketoacidos.& coma/   lign.syndr./high fev.observ., cons. dos. reduct./discont.ther.if S&S of   721746-001: 200 mg, 60, R497,20
   death, cerebrovasc.accid.& TIA’s, orthostat. hypotens., seiz., decr.neu-  tard.dyskines. devel., monit.exist.diab.for worsen.gluc.contr., monit.   721747-001: 300 mg, 60, R561,70
   trophil & thrombocyte count, water intoxicat.from polydips.or inap-  pts.start.treatm.at risk of diab.for hyperglycaem., fast.bld.gluc.if hy-  Dosage: Adults: Admin.twice dly.
   propr. antidiuret. hormone secret., body temp. disregulat., incr.plasma   perglycaem. devel., some pts.req.continuat.of anti-diabet. treatm.   Schizophren: Tot.dly.dos.for 1  4 days: Day 1: 50 mg, day 2: 100 mg,
                                                                           st
   prolact.lev.& manifestat., psych. disords., somnol., imp.conc., CNS   despite.discont., seiz.hist./condits.assoc. with seiz./low.seiz.thresh.,   day 3: 200 mg & day 4: 300 mg. Titr.dos.from 4  day to effect.dos.
                                                                                  th
   effs., dos. depend. extrapyramid.sympts.incl.trem./ rigidity/ hypersali-  hepat.impairm./ concom. potent.hepatotox.meds., period. transamin.   range of 300-450 mg/day. Adjust.dos.within 150-750 mg / day range
   vat./bradykines./oculogyric cris./ akathisia/ ac.dyston.& hypokines.,   monit.in hepat.dis., elderly, concom. centr. act.agents & alcoh., con-  depend.on clinic.respons. & tolerab.
   CVA, blurr. vis., tachycard., hypertens., rhinit., GI disturbs., skin rash,   com.meds.known to incr.QTc interv./congenit.long QT syndr./CHF/  Bipol.disord.assoc.manic episod: Tot.dly.dos. for 1  4 days: Day
                                                                                     st
   urin.incont., erect.-/ejaculat.-/orgasm.dysfunct., priapism, gynaeco-  heart hypertrophy/hypokalaem.& hypomagnesaem., concom. BP low.  1: 100 mg, day 2: 200 mg, day 3: 300 mg & day 4: 400 mg. Furth.dos.
   mast., galactorrh., menstr.cycle disturbs.& amenorrh., headache,   meds.other than alpha-1 adrenerg. antagon., admin.activ.charcoal   adjustm. up to 800 mg/day by day 6 in increm.of no great.than 200
   weight gain, fatig., angio-oed. & other allerg.reacts., imp.ment.alertn.  2 hrs bef./aft. olanzapine, pre-exist.condits.assoc.with limit. hepat.   mg/day. Adjust dos.accord.to clinic. respon. & tolerab.with range of
   Special precautions: High.mortalit.report.in elderly dement.pts.  funct.reserv., discont.ther.if hepatit.diagn., condits.contrib.to elev.body   200-800 mg/day. Usual effect.dos.: 400-800 mg/day.
   receiv.furosemide, avoid dehydrat. in pts.receiv.furosemide, monit.  core temp., monit. high risk suic.pts., symptom.prostat.enlargem.,   Elderly: Init.25 mg/day, theraft.incr.dly.dos.in increm. of 25-50 mg.to
   gluc. control in diab.mellit., diab.mellit.risk fact., high. incid. cerebro-  paralyt. ileus & relat.condits., recent MI hist./ unstab. card.dis., low   an effect.dos.depend.on indiv. respons.& toler.
   vasc.accid.& TIA’s report.in elderly with dement., Parkinson.dis.as at   leucocyte/neutroph.counts, meds.induc.bone marrow depress./toxic.,   Contraindications: Safety in advanc.liv.& ren. impairm./ pregn.&
   risk of NMS & incr. antipsychot.med.sensitiv., high.mortalit. report. in   bone marrow depress.aft.illn./radiat.& chemother., hypereosinophil.  lactat.not est., safety & effic.in childr.& adolesc.und.18 yrs.not est.,
   elderly treat.pts., concom.alcoh.& other central. act.meds., known CV   condits., myeloproliferat.dis., concom. CYP1A2 inhibit./induc., pts.at   not indic.for elderly pts.with dement.-relat.psychos., concom. P450
   dis.where grad.dos. titrat. recomm., consid.dos.reduct.if hypotens. de-  risk of aspirat.pneum., pre-exist.risk fact.for CVAE, concom. carbamaz-  3A4 inhibits., lact.intol.
   velops, epilep., post-market.advers.effs. observ. in neonates expos.dur.  epine/smok., cons.low.start. dos. in case of fact.decr.pharmacokinet.  Side effects: Hyperglycaem.sometim.extreme assoc. with ketoaci-
   last trimest.of pregn., excret. in human breast milk, ren.& liv. impairm.,   clear./incr. pharmacodynam.respons., concom.fluoxetine not advis.,   dos./hyperosmol.coma/death, poss. sev.neutropen., somnol., dizzin.,
   sometimes diffic.to differen.advers. effs. from sympts.of underly.psy-  do not combin.inj.in same syringe as diazepam/ haloperidol, do not   dry mouth, asthen. GI disturbs., dysphag., tachycard., orthostat. hypo-
   chos., TD risk incr. with ther.durat.& tot.cumulat.dos., prescrib. in man-  reconstit. with lorazepam, most ser.cases of symptomat. hypotens./   tens., weight gain, CNS effs., neurolept. malign.syndr., bld.disords.,
   ner to minim.TD risk, reserve treatm.for pts. obtain.substant.benef.,   apnoea & ventric.tachydysrhythm.with IM use had temporal relation-  periph.oed., headache, dysarth., anx., extrapyramid.sympt./ syndr.,
   reg.assess contin. ther., with S&S of tard.dyskines.consid.discont.,   ship to benzodiazepine use, ser.CV dis.where syncope/ hypotens./   hyperton., hypokines., seiz., tard./dyskines., restless leg.syndr., psych.
   discont. all anti-psychot.& not essent.meds.if neurolept. malign.syndr.  bradycard.incr.medic.risk, concom. parenteral olanzapine& benzo-  disords., palpitat., asthen., withdr.sympt., pyrex., myalg., hypotherm.,
   develops & instit.treatm., consid. re-introduct.caref.& monit.aft.NMS   diazepine not recomm., if consid.necess.parenter.benzodiazep.to be   jaund., hepatit., rhinit., chest/back/ear pain, dyspn., hypersens.incl.
   recov. as NMS recurr.report., preventat.hypo-oestrog. bone loss ther.in   admin.at least 1 hr.aft.IM olanzapine, if parenteral benzodiazep.al-  angioed./anaphylax., Stev. Johns. syndr., ven.thromboembol., elev.
   premenopaus.women with second. amenorrh. of &gt;6mnths., refrain from   ready admin.IM olanzapine should only be consid.aft.caref.clinic. eval.   ser. transamin./ cholester. & triglycer., incr.bld.gluc.to hyperglycaem.
   excess. eat., no caus.assoc.detect.with report benign pituit.adenomas.  & pt.to be caref.mont.for excess.sedat.& card. resp.depess., period.  lev., sex.dysfunct., priapism, galactorrh., breast swell., menstr.disor-
   Drug interactions: Use with other concom. meds. not system.eval.,   BP monit.in pts.over 65 yrs., ODT & tabs.cont.lact., IMI cont.maltose  ds., inappropr. antidiuret.horm.secret., hypothyroid., rhabdomyolys.,
   may antagon.eff.of levodopa & other dopamine agonists, carbamaz-  Drug interactions: Fluoxetine decr.clear., may antagon. effs.of lev-  diab.mellit./exacerbat.of pre-exist. diab., hyponatraem., dry eyes,
   epine & other hepat.enzyme induc.may decr.plasma lev., incr.plasma   odopa & dopamine agon., may enhanc. effs.of cert.antihypertens.,   blurr. vis., cataract format., UTI, ac.withdr.sympt.aft.abrupt withdr.,
   lev.with phenothiaz. /TCA’s/some ß-block./fluoxetine.& paroxet., ci-  reduc.eff.with activat. charc., clear.decr.by known potent CYP1A2   suic./ relat.events in pts.&lt; 18 yrs.
   metidine & ranitidine incr.bioavailabil.  inhibit., metabol.poss.induc.by concom.smok./ carbamazepine low.  Special precautions: Monit.gluc.contr.of exist. diabet./ hypergly-
   PREXOLAN, (Aspen Pharmacare: Pharma) Pharmacare [P/S]  plasma lev., CNS depress.& alcoh.  caem., pts.develop. hyperglycaem. sympt.dur.ther. to undergo fast.
   Olanzapine                   PSYQUET, (Biogaran) Sandoz [P/S]  bld. gluc. test, cont.anti-diab.meds.poss.necess. despite ther.discont.,
   Indications: Managem.of psychot.disord. manifestat., ac.mania &   Quetiapine.  benef./risk assessm.in elderly pts.with dement.tak.stroke risk into
   prev.recurr.of manic/ depress.episod.of bipol.disord.  Indications: Schizophren., manic episod.assoc. with bi-polar disord.   account, monit.elderly esp.dur.init.dos.per., stroke/ VTE risk fact.,
   (S5) ORODISP.TABS (ODT), 44/2.6.5/0915, 0916  for which safety & effic. beyond 12 wks. not demonstrat.  discont.ther.if neutroph.count &lt;1,0X 109/t /jaund./neurolept.malign.
   719806-001: 5 mg, 30, R482,40  (S5) TABS. 43/2.6.5/0446, 0849, 0850, 0851  syndr.sympt./tard. dyskines. S&S devel., tard.dyskines.sympt.poss.
   719807-001: 10 mg, 30, R618,30  718352-002: 25 mg, 30, R78,98  arise/ wors.aft.ther.discont., aspirat.pneumon. risk, subst.abuse/seiz.
   (S5) TABS, 43/2.6.5/0908, 0909, 0910  718352-001: 25 mg, 105, R276,46  hist., concom.antihypertens. /meds. prolong.QTc interv., poss.dos.
   Indications: Managem.of schizophren. manifestat., ac.mod.to   718353-001: 100 mg, 90, R452,48  adjustm.with phenytoin/other concom.hepat.enzyme induc., reduc.
   sev.mania episode & prevent. recurr.of manic/depress.episod.of   718354-001: 200 mg, 60, R486,68  dos.with non-induc.eg.sod.valproate, known CV/ cerebrovasc. dis./
   bipol. disord.               718355-001: 300 mg, 60, R568,84  condits.predispos.to hypotens., withdr.grad., caref.monit.of high-risk
   720712-001: 2,5 mg, 30, R370,86  Dosage: Adults: Admin.twice dly.  pts. incl.suic./clinic.worsen., QT prolongat.fam. hist./ concom.meds.
                                             st
   720713-001: 5 mg, 30, R467,70  Schizophren: Tot.dly.dos.for 1  4 days: Day 1: 50 mg, day 2: 100 mg,   known to incr.QT-interv./ concom. neurolept.esp.pts.with incr.risk of
   720714-001: 10 mg, 30, R608,10  day 3: 200 mg & day 4: 300 mg. Titr.dos.from 4  day to effect.dos.  QT prolongat., ren./hepat.impairm., lipid chang.
                                                    th</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page56.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page52.html">52</a>&nbsp;&nbsp;&nbsp;<a href="page53.html">53</a>&nbsp;&nbsp;&nbsp;<a href="page54.html">54</a>&nbsp;&nbsp;&nbsp;<a href="page55.html">55</a>&nbsp;&nbsp;&nbsp;<a href="page56.html">56</a>&nbsp;&nbsp;&nbsp;<a href="page57.html">57</a>&nbsp;&nbsp;&nbsp;<a href="page58.html">58</a>&nbsp;&nbsp;&nbsp;<a href="page59.html">59</a>&nbsp;&nbsp;&nbsp;<a href="page60.html">60</a>&nbsp;&nbsp;&nbsp;<a href="page61.html">61</a>&nbsp;&nbsp;&nbsp;<a href="page62.html">62</a>
             </td>
             <td width="35%"><a href="page58.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page58.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
